StockMacro
Company, fund or insider

Help

Menu

IN8bio

$0.76 -55% in 6 monthsMarket cap $8.2M

INAB on XNAS, Health Care, IN8bio, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 52% in a year while cash of $14.2M exceeds the $8.3M market value.

  • BadShares down 30% in one month and 55% in six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
20
Website
in8bio.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 11 Mar 2027 (an estimate: a year ago it reported on 12 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $4.6M.
Quarter to 31 Dec 2021: revenue –, net income -$5.8MQuarter to 31 Mar 2022: revenue –, net income -$6.1MQuarter to 30 Jun 2022: revenue –, net income -$7.2MQuarter to 30 Sep 2022: revenue –, net income -$7.4MQuarter to 31 Dec 2022: revenue –, net income -$7.8MQuarter to 31 Mar 2023: revenue –, net income -$7.5MQuarter to 30 Jun 2023: revenue –, net income -$7.7MQuarter to 30 Sep 2023: revenue –, net income -$7.2MQuarter to 31 Dec 2023: revenue –, net income -$7.6MQuarter to 31 Mar 2024: revenue –, net income -$8.6MQuarter to 30 Jun 2024: revenue –, net income -$8.6MQuarter to 30 Sep 2024: revenue –, net income -$7.1MQuarter to 31 Dec 2024: revenue –, net income -$6.2MQuarter to 31 Mar 2025: revenue –, net income -$5.5MQuarter to 30 Jun 2025: revenue –, net income -$5.1MQuarter to 30 Sep 2025: revenue –, net income -$3.9MQuarter to 31 Dec 2025: revenue –, net income -$4.9MQuarter to 31 Mar 2026: revenue –, net income -$5.1MQuarter to 30 Jun 2026: revenue –, net income -$4.8MQuarter to 30 Sep 2026: revenue –, net income -$4.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $8.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$4.6M
30 Jun 2026–-$4.8M
31 Mar 2026–-$5.1M
31 Dec 2025–-$4.9M
30 Sep 2025–-$3.9M
30 Jun 2025–-$5.1M
31 Mar 2025–-$5.5M
31 Dec 2024–-$6.2M
30 Sep 2024–-$7.1M
30 Jun 2024–-$8.6M
31 Mar 2024–-$8.6M
31 Dec 2023–-$7.6M
30 Sep 2023–-$7.2M
30 Jun 2023–-$7.7M
31 Mar 2023–-$7.5M
31 Dec 2022–-$7.8M
30 Sep 2022–-$7.4M
30 Jun 2022–-$7.2M
31 Mar 2022–-$6.1M
31 Dec 2021–-$5.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$19.4M -$20.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -142% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $14.2M $11.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$14.2M (net cash) -$11.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.31
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.58 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
IN8bioINAB (this company) $8.2Mloss–––
Intensity TherapeuticsINTS $8.2Mloss–––
Black Hawk AcquisitionBKHA $7.7M5.9–––
Aligos TherapeuticsALGS $7.6Mloss1.3+122%–
Jasper TherapeuticsJSPR $9.6Mloss–––
aTyr PharmaATYR $9.7Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

21 13F filers vs 21

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

34%

3.7M shares held by 13F filers (30 Sep 2026) of 10.8M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.1%

16K shares sold short (30 Oct 2026) of 10.8M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

16K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-52%

33K shares sold short in the report before, 16K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

4.7%

4.7% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.76 on 20 Nov 2026, -52% over 12 months (12-month range $0.76 to $2.59)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 21 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Jun 20268-K and other filingsA major agreement ended
7 May 20268-K and other filingsDirector or officer change
27 Feb 20268-K and other filingsDirector or officer change
9 Feb 20268-K and other filingsDirector or officer change
9 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Dec 20258-K and other filingsPrivate placement of securities (Form D)
17 Jun 2025Sharp changeShort interest spike: short interest spike, 3.0M vs usual 481K (2025-05-30); 45.6x the same period a year earlier
5 Mar 20258-K and other filingsDirector or officer change
5 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Mar 2025Sharp changeShort interest spike: short interest spike, 3.8M vs usual 262K (2025-02-14); 91.6x the same period a year earlier
7 Feb 20258-K and other filingsDelisting notice or listing transfer
28 Jan 2025Sharp changeShort interest spike: short interest spike, 900K vs usual 193K (2025-01-15); 10.4x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 964K vs usual 184K (2024-12-13); 1.8x the same period a year earlier
17 Dec 2024Sharp changeShort interest spike: short interest spike, 859K vs usual 178K (2024-11-29); 9.7x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 162K (2024-11-15); 48.4x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 1.0M vs usual 138K (2024-10-31); 17.8x the same period a year earlier
15 Oct 20248-K and other filingsPrivate placement of securities (Form D)
11 Sep 20248-K and other filingsDirector or officer change
6 Sep 20248-K and other filingsDirector or officer change
6 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Sep 20248-K and other filingsRestructuring costs announced
16 Jul 2024Sharp changeShort interest spike: short interest spike, 757K vs usual 85K (2024-06-28); 10.9x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 512K vs usual 85K (2024-04-15); 3.5x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 525K vs usual 90K (2023-12-15); 5.1x the same period a year earlier
28 Dec 20238-K and other filingsPrivate placement of securities (Form D)
7 Dec 20238-K and other filingsDirector or officer change
7 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 May 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 50K (2023-04-28); 92.4x the same period a year earlier
1 May 20238-K and other filingsDirector or officer change
1 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Aug 2022Sharp changeClustered insider buying: clustered insider buying (9 independent filers, 10 filing(s) in 30 days, value_usd total 5.3M)
9 Aug 20228-K and other filingsRegistered new securities for sale (S-1)
8 Aug 20228-K and other filingsRegistered new securities for sale (S-1)
9 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Aug 2022: $5.4M published
Month from 1 Sep 2022: $50K published
Month from 1 Dec 2022: $186K published
Month from 1 Aug 2023: $26K published
Month from 1 Sep 2023: $2K published
Capital spending per quarter
Quarter ended 31 Mar 2022: $8K; public on 13 May 2023
Quarter ended 30 Jun 2022: $1K; public on 11 Aug 2023
Quarter ended 31 Mar 2023: $371K, +4538% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $36K, +3500% on a year earlier; public on 11 Aug 2023
Quarter ended 31 Mar 2024: $50K, -87% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $21K, -42% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 7 Nov 2025
Institutional holders (13F filers)
31 Dec 2021 report: 15; public on 14 Feb 2022
31 Mar 2022 report: 14; public on 16 May 2022
30 Jun 2022 report: 16; public on 15 Aug 2022
30 Sep 2022 report: 18; public on 14 Nov 2022
31 Dec 2022 report: 16; public on 14 Feb 2023
31 Mar 2023 report: 17; public on 15 May 2023
30 Jun 2023 report: 21; public on 14 Aug 2023
30 Sep 2023 report: 20; public on 14 Nov 2023
31 Dec 2023 report: 30; public on 14 Feb 2024
31 Mar 2024 report: 31; public on 15 May 2024
30 Jun 2024 report: 25; public on 14 Aug 2024
30 Sep 2024 report: 22; public on 14 Nov 2024
31 Dec 2024 report: 26; public on 14 Feb 2025
31 Mar 2025 report: 28; public on 15 May 2025
30 Jun 2025 report: 11; public on 14 Aug 2025
30 Sep 2025 report: 18; public on 14 Nov 2025
31 Dec 2025 report: 22; public on 17 Feb 2026
31 Mar 2026 report: 19; public on 15 May 2026
30 Jun 2026 report: 21; public on 14 Aug 2026
30 Sep 2026 report: 21; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash from operations, fiscal year at -$12.7M (31 Dec 2025), 46% below its normal quarter of -$23.3M; higher than 83% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $0 in the latest quarter.
  • Institutional holders (13F filers): 21 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 23 insider trades

No trades in the last 90 days; the latest was filed 15 Sep 2023. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
15 Sep 2023Jeremy R. GraffDirectorBuy2,500$0.95$2KForm 4
28 Aug 2023Patrick McCallChief Financial OfficerBuy1,000$1.03$1KForm 4
28 Aug 2023William Tai-Wei HoPresident and CEOBuy23,800$1.05$25KForm 4
13 Dec 2022BIOS Fund III QP, LP and 9 othersDirector, 10% ownerBuy75,001$2.48$186KForm 4
29 Sep 2022Bios Equity Partners II, LP and 4 othersDirector, 10% ownerBuy25,000$2.02$50KForm 4
30 Aug 2022Cavu Advisors, LLC and 8 othersDirector, 10% ownerBuy51,214$2.02$103KForm 4
18 Aug 2022Trishna GoswamiChief Medical OfficerBuy2,631$1.90$5KForm 4
18 Aug 2022William Tai-Wei HoPresident, CEO and CFOBuy26,315$1.90$50KForm 4

21 institutions reported shares at the end of Q3 2026, 34% of the shares outstanding; 2 opened a position, 2 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Alyeska Investment Group, L.P.944K8.74%$1.3MNo change
Franklin Templeton Inc915K8.46%$851KNo change
683 Capital Management, LLC725K6.70%$964KNo change
Stonepine Capital Management, LLC698K6.46%$928K+2,565+0.4%
Vanguard Capital Management LLC89K0.82%$118KNo change
BIOS Capital Management, LP81K0.75%$108KNo change
Geode Capital Management, LLC63K0.58%$84K-9,599-13%
Vanguard Fiduciary Trust Co44K0.40%$58KNo change
UBS Group AG37K0.34%$49K+37K36,953 times as many
Renaissance Technologies LLC34K0.31%$45K+22K+180%

Company events

All 31 company events

In 12 months: 3 director or officer changes, 2 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Jun 2026Signed a major agreement; A major agreement ended8-K
7 May 2026Director or officer changeSame filing: shareholder vote results8-K
27 Feb 2026Director or officer change8-K
9 Feb 2026Director or officer change8-K
30 Dec 2025Private placement of securities (Form D)$20.1M sold of $40.2M offeredD
19 Dec 2025Signed a major agreementSame filing: sold shares privately8-K
28 Apr 2025Signed a major agreementSame filing: sold shares privately, changed shareholder rights8-K
5 Mar 2025Director or officer change8-K

The 5 newest of 17 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 1 Jun 2026Filings record

    A major agreement ended

  2. 7 May 2026Filings record

    Director or officer change

  3. 27 Feb 2026Filings record

    Director or officer change

  4. 9 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 9 Feb 2026Filings record

    Director or officer change

  6. 30 Dec 2025Filings record

    Private placement of securities (Form D)

  7. 11 Jun 2025Short interest and volume change

    had 3.0M shares sold short in the 30 May 2025 report, 46× the same report last year.

    Same report last year: 66K; its normal report is 481K.

    See the evidence
    This period
    3.0M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    481K
    Typical spread (median absolute deviation)
    312K
    How far from its usual level
    +5.5
    Same report last year
    66K
    History used
    1,386 days
    2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M2024-11-29: 859K2024-12-13: 964K2024-12-31: 484K2025-01-15: 900K2025-01-31: 433K2025-02-14: 3.8M2025-02-28: 801K2025-03-14: 1.7M2025-03-31: 1.0M2025-04-15: 478K2025-04-30: 426K2025-05-15: 1.2M2025-05-30: 3.0M
    the 30 May 2025 report24 earlier reportsnormal: 481K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 5 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 5 Mar 2025Filings record

    Director or officer change

  10. 27 Feb 2025Short interest and volume change

    had 3.8M shares sold short in the 14 Feb 2025 report, 92× the same report last year.

    Same report last year: 41K; its normal report is 262K.

    See the evidence
    This period
    3.8M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    262K
    Typical spread (median absolute deviation)
    196K
    How far from its usual level
    +12.1
    Same report last year
    41K
    History used
    1,281 days
    2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M2024-11-29: 859K2024-12-13: 964K2024-12-31: 484K2025-01-15: 900K2025-01-31: 433K2025-02-14: 3.8M
    the 14 Feb 2025 report24 earlier reportsnormal: 262K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 7 Feb 2025Filings record

    Delisting notice or listing transfer

  12. 28 Jan 2025Short interest and volume change

    had 900K shares sold short in the 15 Jan 2025 report, 10× the same report last year.

    Same report last year: 87K; its normal report is 193K.

    See the evidence
    This period
    900K (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    193K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +3.5
    Same report last year
    87K
    History used
    1,251 days
    2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M2024-11-29: 859K2024-12-13: 964K2024-12-31: 484K2025-01-15: 900K
    the 15 Jan 2025 report24 earlier reportsnormal: 193K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 25 Dec 2024Short interest and volume change

    had 964K shares sold short in the 13 Dec 2024 report, 1.8× the same report last year.

    Same report last year: 525K; its normal report is 184K.

    See the evidence
    This period
    964K (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    184K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +4.8
    Same report last year
    525K
    History used
    1,218 days
    2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M2024-11-29: 859K2024-12-13: 964K
    the 13 Dec 2024 report24 earlier reportsnormal: 184K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 11 Dec 2024Short interest and volume change

    had 859K shares sold short in the 29 Nov 2024 report, 9.7× the same report last year.

    Same report last year: 89K; its normal report is 178K.

    See the evidence
    This period
    859K (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    178K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +4.7
    Same report last year
    89K
    History used
    1,204 days
    2023-11-30: 89K2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M2024-11-29: 859K
    the 29 Nov 2024 report24 earlier reportsnormal: 178K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 27 Nov 2024Short interest and volume change

    had 1.3M shares sold short in the 15 Nov 2024 report, 48× the same report last year.

    Same report last year: 28K; its normal report is 162K.

    See the evidence
    This period
    1.3M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    162K
    Typical spread (median absolute deviation)
    89K
    How far from its usual level
    +8.9
    Same report last year
    28K
    History used
    1,190 days
    2023-11-15: 28K2023-11-30: 89K2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M2024-11-15: 1.3M
    the 15 Nov 2024 report24 earlier reportsnormal: 162K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 13 Nov 2024Short interest and volume change

    had 1.0M shares sold short in the 31 Oct 2024 report, 18× the same report last year.

    Same report last year: 56K; its normal report is 138K.

    See the evidence
    This period
    1.0M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    138K
    Typical spread (median absolute deviation)
    77K
    How far from its usual level
    +7.6
    Same report last year
    56K
    History used
    1,175 days
    2023-10-31: 56K2023-11-15: 28K2023-11-30: 89K2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K2024-07-15: 458K2024-07-31: 245K2024-08-15: 278K2024-08-30: 198K2024-09-13: 189K2024-09-30: 177K2024-10-15: 147K2024-10-31: 1.0M
    the 31 Oct 2024 report24 earlier reportsnormal: 138K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 15 Oct 2024Filings record

    Private placement of securities (Form D)

  18. 11 Sep 2024Filings record

    Director or officer change

  19. 6 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 6 Sep 2024Filings record

    Director or officer change

  21. 4 Sep 2024Filings record

    Restructuring costs announced

  22. 11 Jul 2024Short interest and volume change

    had 757K shares sold short in the 28 Jun 2024 report, 11× the same report last year.

    Same report last year: 69K; its normal report is 85K.

    See the evidence
    This period
    757K (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    85K
    Typical spread (median absolute deviation)
    32K
    How far from its usual level
    +13.4
    Same report last year
    69K
    History used
    1,050 days
    2023-06-30: 69K2023-07-14: 85K2023-07-31: 25K2023-08-15: 46K2023-08-31: 87K2023-09-15: 37K2023-09-29: 99K2023-10-13: 56K2023-10-31: 56K2023-11-15: 28K2023-11-30: 89K2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K2024-04-30: 180K2024-05-15: 106K2024-05-31: 66K2024-06-14: 390K2024-06-28: 757K
    the 28 Jun 2024 report24 earlier reportsnormal: 85K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 25 Apr 2024Short interest and volume change

    had 512K shares sold short in the 15 Apr 2024 report, 3.5× the same report last year.

    Same report last year: 145K; its normal report is 85K.

    See the evidence
    This period
    512K (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    85K
    Typical spread (median absolute deviation)
    32K
    How far from its usual level
    +8.5
    Same report last year
    145K
    History used
    976 days
    2023-04-14: 145K2023-04-28: 1.2M2023-05-15: 138K2023-05-31: 77K2023-06-15: 89K2023-06-30: 69K2023-07-14: 85K2023-07-31: 25K2023-08-15: 46K2023-08-31: 87K2023-09-15: 37K2023-09-29: 99K2023-10-13: 56K2023-10-31: 56K2023-11-15: 28K2023-11-30: 89K2023-12-15: 525K2023-12-29: 116K2024-01-12: 87K2024-01-31: 129K2024-02-15: 41K2024-02-29: 21K2024-03-15: 85K2024-03-28: 52K2024-04-15: 512K
    the 15 Apr 2024 report24 earlier reportsnormal: 85K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 28 Dec 2023Short interest and volume change

    had 525K shares sold short in the 15 Dec 2023 report, 5.1× the same report last year.

    Same report last year: 102K; its normal report is 90K.

    See the evidence
    This period
    525K (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    90K
    Typical spread (median absolute deviation)
    34K
    How far from its usual level
    +8.7
    Same report last year
    102K
    History used
    854 days
    2022-12-15: 102K2022-12-30: 132K2023-01-13: 118K2023-01-31: 106K2023-02-15: 91K2023-02-28: 208K2023-03-15: 165K2023-03-31: 150K2023-04-14: 145K2023-04-28: 1.2M2023-05-15: 138K2023-05-31: 77K2023-06-15: 89K2023-06-30: 69K2023-07-14: 85K2023-07-31: 25K2023-08-15: 46K2023-08-31: 87K2023-09-15: 37K2023-09-29: 99K2023-10-13: 56K2023-10-31: 56K2023-11-15: 28K2023-11-30: 89K2023-12-15: 525K
    the 15 Dec 2023 report24 earlier reportsnormal: 90K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 28 Dec 2023Filings record

    Private placement of securities (Form D)

  26. 7 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 7 Dec 2023Filings record

    Director or officer change

  28. 16 Sep 2023Insiders record

    Graff Jeremy R. (director) bought 2,500 shares of INAB ($2,375) (dated 15 Sep 2023)

  29. 29 Aug 2023Insiders record

    McCall Patrick (Chief Financial Officer) bought 1,000 shares of INAB ($1,030) (dated 28 Aug 2023)

  30. 29 Aug 2023Insiders record

    Ho William Tai-Wei (President and CEO) bought 23,800 shares of INAB ($24,990) (dated 28 Aug 2023)

  31. 10 May 2023Short interest and volume change

    had 1.2M shares sold short in the 28 Apr 2023 report, 92× the same report last year.

    Same report last year: 13K; its normal report is 50K.

    See the evidence
    This period
    1.2M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    50K
    Typical spread (median absolute deviation)
    37K
    How far from its usual level
    +20.7
    Same report last year
    13K
    History used
    623 days
    2022-04-29: 13K2022-05-13: 13K2022-05-31: 17K2022-06-15: 13K2022-06-30: 10K2022-07-15: 9,2392022-07-29: 13K2022-08-15: 41K2022-08-31: 34K2022-09-15: 86K2022-09-30: 51K2022-10-14: 44K2022-10-31: 40K2022-11-15: 49K2022-11-30: 70K2022-12-15: 102K2022-12-30: 132K2023-01-13: 118K2023-01-31: 106K2023-02-15: 91K2023-02-28: 208K2023-03-15: 165K2023-03-31: 150K2023-04-14: 145K2023-04-28: 1.2M
    the 28 Apr 2023 report24 earlier reportsnormal: 50K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 1 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 1 May 2023Filings record

    Director or officer change

  34. 14 Dec 2022Insiders record

    BIOS Fund III QP, LP (director) and 9 other(s) bought 75,001 shares of INAB ($186,002) (dated 13 Dec 2022)

  35. 14 Dec 2022Insiders record

    Kreis Leslie W. (director) and 4 other(s) bought 75,001 shares of INAB [same transaction as an earlier filing] (dated 13 Dec 2022)

  36. 30 Sep 2022Insiders record

    Bios Equity Partners II, LP (director) and 4 other(s) bought 25,000 shares of INAB ($50,500) (dated 29 Sep 2022)

  37. 30 Sep 2022Insiders record

    BIOS Fund II NT, LP (director) and 9 other(s) bought 25,000 shares of INAB [same transaction as an earlier filing] (dated 29 Sep 2022)

  38. 31 Aug 2022Insiders record

    BIOS Fund II QP, LP (director) and 8 other(s) bought 51,214 shares of INAB [same transaction as an earlier filing] (dated 30 Aug 2022)

  39. 31 Aug 2022Insiders record

    Cavu Advisors, LLC (director) and 8 other(s) bought 51,214 shares of INAB ($103,340) (dated 30 Aug 2022)

  40. 19 Aug 2022Insiders change

    had 9 insiders buy $5.3M of its shares on the open market within 30 days (10 filings).

    Who bought: Lamb Lawrence, Brandt Peter C., Greenwood Luba, McCall Patrick and 3 more.

    See the evidence (10 source records)
    Independent buyers
    9
    Purchase filings (Form 4, code P)
    10
    Total bought
    $5.3M
    Window
    20 Jul 2022 to 19 Aug 2022

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Showing the newest 40 of 66 entries; narrow the window or the kind of data to see older ones.

Not listed: 78 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001740279
Ticker
INAB
Domain
in8bio.com
Hq location
NY|NEW YORK|10118 (1 unverified)
Name
IN8bio, Inc., Incysus Therapeutics, Inc.
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)103 records22 May 2018 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)302 data points31 Dec 2019 to 2 Nov 2026
  • SEC Form 4 insider transactions23 records, 32 data points3 Aug 2021 to 15 Sep 2023
  • FINRA short interest (twice monthly)374 data points13 Aug 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2656 data points30 Jul 2021 to 20 Nov 2026